Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Approved
Recipient : Lipocine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lipocine And SPC Korea Partner to Commercialize TLANDO® in South Korea
Details : Under the term of license agreement, SPC will gain exclusive rights to market Tlando (testosterone undecanoate) in South Korea. It is indicated for the primary and hypogonadotropic hypogonadism.
Brand Name : Tlando
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 05, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Recipient : Lipocine
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?